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Introduction: Disease burden due to tobacco smoking in Latin America remains 
very high. The objective of this study was to evaluate potential impact of 
implementing smoke-free air interventions on health and cost outcomes in Argentina, 
Bolivia, Brazil, Chile, Colombia, Mexico, and Peru, using a mathematical model. 
Methods: We built a probabilistic Montecarlo microsimulation model, considering 
natural history, direct health system costs and quality of life impairment associated 
with main tobacco-related diseases. We followed individuals in hypothetical cohorts 
and calculated health outcomes on an annual basis to obtain aggregated 10-year 
population health outcomes (deaths, events) and costs. To populate the model, we 
completed an overview and systematic review of literature. Also, we calibrated the 
model comparing the predicted disease-specific mortality rates with those coming 
from local national statistics.  
Results: With current policies, over 10 years, of 137,121 deaths and 917,210 events 
could be averted, adding 3.84 million years of healthy life and saving USD 9.2 billion 
in these seven countries. If countries fully implemented smoke-free air strategies, it 
would be possible avert nearly 180,000 premature deaths and 1,2 million events, 
adding 5 million healthy years of life and saving USD 13.1 billion in direct healthcare. 
Conclusion: Implementing the smoke-free air strategy would substantially reduce 
deaths, diseases, and health care costs attributed to smoking. Latin American 
countries should not delay the full implementation of this strategy. 
 
 
Implications: Tobacco smoking is the single most preventable and premature 
mortality cause in the world. The Framework Convention on Tobacco Control, 
supported by the World Health Organization, introduced a package of evidence-
based measures for tobacco control. This study adds quality evidence on the 
potential health effects and savings of implementing smoke-free air policies in 





















What this study adds:  
Smoking remains a leading risk factor for early death and disability in more than 100 
countries with 11.5% deaths and 6% of disability-adjusted life-years worldwide 1. We found 
that the full implementation of smoke-free policies would lead to a total economic benefit of 























Smoking is responsible for six million deaths every year and, by 2020, this toll is 
expected to rise to seven and a half million, killing one billion people in the twenty-
first century.2,3 People killed by tobacco-related disease lose approximately 20 years 
of life expectancy compared with persons who have never smoked.4 Moreover, 
tobacco is responsible for a large proportion of disability-adjusted life years (DALYs); 
ranging, in the studied countries, from 11.3% in Uruguay to 2.1% in Ecuador.5 In 
Latin America, smoking is associated with one million deaths per year, the third 
leading risk factor for death and lost years of healthy life and contributes to poverty 
with decreased productivity and an impact on out-of-pocket expenses.6  
Worldwide, diseases and premature death are caused by second-hand smoke 
(SHS), a mixture of mainstream smoke exhaled by the smoker, and side stream, 
released from the cigarette, containing toxicants and carcinogens.7-9 In 2001, the 
Pan American Health Organization (PAHO) launched the Smoke-Free Americas 
initiative to promote smoke-free communities, workplaces and homes; in 2005, the 
World Health Organization Framework Convention on Tobacco Control (WHO-
FCTC) entered into force, with 181 countries committed, 30 of these are in the 
Americas.4,10 Almost every nation in the Latin American region has signed the FCTC, 
but many are still lacking a strong tobacco-control policy.4,10 Smoking-related 
diseases cause a significant economic burden on individuals and health systems, 
which can reach US$ 500 billion annually worldwide, including productivity loss, 
illnesses and premature deaths, and representing up to 1.5% of the GDP of some 
high-income nations and up to 15% of all national health expenditures.4,11,12 In fact, 
in Latin Ameri a, smoking accounts for about US$ 34 billion every year, and it 
represents 5.2% of the health budget in Brazil and up to 12.7% in Bolivia.13  
Smoke-free policies, cornerstone of the FCTC, limit where smokers can smoke and 
therefore reduce involuntary exposure to toxic second-hand tobacco smoke, reduce 
tobacco consumption, and promoted quitting.14 Mexico introduced implemented 
state-wide smoke-free air regulations in 2009 and by 2013, smoke-free policy 
coverage reached 40% of total population.15 In Argentina 21.8% of workers are still 




















implementation of 100% smoke-free interventions in all closed public access sites 
and workplaces is the only way to ensure that all people are protected from tobacco 
smoke. It has been estimated that comprehensive smoke-free laws after the 
adoption of MPOWER policy resulted in 5.4 million less smoking-attributable deaths 
from 2007 and 2014.17 
However, misinformation, prejudice, lack of quality information at a country-level and 
pressure from interest groups have delayed the implementation and enforcement of 
measures in the region.6,18 Our objective is twofold: to report the tobacco-related 
burden of mortality, disease and direct costs imposed on the health systems in Latin 
America as well as to predict the health and financial impact of implementing smoke-
free policies throughout the region. 
METHODS 
The analysis was conducted using a probabilistic state-transition microsimulation model (i.e. 
individual-based Markov model, or first-order Monte Carlo technique) developed specifically 
to estimate the burden of smoking-attributable disease and the cost-effectiveness of tobacco 
control policies and interventions.19 The model was validated and used to estimate the 
burden of disease attributable to smoking and the potential impact of different 
interventions.13,20-25 We performed a comprehensive analysis of epidemiological and cost 
data and policy-makers’ information needs for the implementation of smoke-free air 
intervention.  
The model considers the natural history, costs and quality of life losses associated with main 
tobacco-related diseases (coronary and non-coronary heart disease, cerebrovascular 
disease, chronic obstructive pulmonary disease, pneumonia, influenza, lung cancer and nine 
other neoplasms). We applied the International Society for Pharmacoeconomics and 
Outcomes Research criteria for model development and reporting.26  
Simulating each individual’s lifetime, we followed up individuals in hypothetical cohorts and 
calculated health outcomes on an annual basis to obtain aggregated long-term population 
health outcomes and costs. For acute events, we calculated age and gender-specific 
absolute risks based on mortality rates and the lethality of the event. Then, we calculated the 
baseline risk for non-smokers based on smoking prevalence per age and sex, and relative 
risk of smoking on that disease. For cancers, we obtained incidence statistics for each age, 




















The main outcomes are life years, quality-adjusted life years, disease events, 
hospitalisations, disease incidence and disease costs. We calculated years of life lost (YLL) 
due to smoking-related diseases at a population level as the sum of years of life lost due to 
premature death (PYLL); and years of life lost due to living with a poor quality of life (YLL-
QL). Tobacco control policies have an effect mediated by a reduction in consumption; this 
lower consumption at the country level is a consequence of a reduction in number of 
cigarettes smoked per smoker, lower tobacco prevalence due to an increase in quitting rates 
(short term) and lower tobacco initiation rates in the medium and long term.  
Effectiveness achieved by current measures for the smoke-free environments was adjusted 
according to degree of compliance, assuming that degree of compliance reflected the 
proportion of benefit achieved relative to the comparator (no intervention or previous step 
within the possible measures) as follows: 
 
𝐸𝑓𝑟 = 𝐶𝑜𝑚 + (𝐸𝑓𝑡 − 𝐶𝑜𝑚) ∗ 𝐺𝑐 
 
Where Efr is actual effectiveness achieved by current measures under current degrees of 
compliance (measured as a relative percentage in the reduction in prevalence); Com is 
effectiveness of the comparator; Eft is the theoretical effectiveness that current measures 
could achieve under the maximum level of compliance; and Gc is the degree of compliance 
of current measures (measured as a ratio of 0 to 1). 
Using the simulation of each individual’s lifetime, individuals in hypothetical cohorts were 
followed-up, and health outcomes were calculated for each subject on an annual basis to 
obtain aggregated population health outcomes and costs. The model updates the values of 
input parameters for each subject on a yearly basis and calculates event rates for outcomes 
based on the covariables and underlying risk equations. The model estimates individual 
lifetime risks of occurrence of each event, disease progression and death, based on the 
subject’s demographic attributes, smoking status and clinical conditions.19,20,24,25,28 To 
estimate the potential impact of tobacco control policies we analysed three scenarios in each 
country. We assumed a lineal evolution from the first scenario to the second one within five 
years, and then to the third scenario between years six to ten. 
a. Short-term scenario (1 year): we assumed that a 50% reduction in 
consumption would have an impact on prevalence (Ip=0.5) and that a 




















smokers. This conservative scenario is more likely to occur in the short term 
(1 year), as it does not include effects that the intervention may have in 
preventing people from starting to smoke or the health benefits of smoking 
fewer cigarettes for those who continue smoking.  
b. Mid-term scenario, (2 to 5 years): similar to the previous scenario, but it 
incorporates potential effects of reduction in the number of cigarettes smoked. 
Although this is a controversial point and this reduction in risk varies 
according to each disease, we assumed that a reduction in consumption 
implies a reduction in excess risk of smoking 29,30. This risk reduction was only 
applied to up to 75% of the total of excess risk separating a smoker from a 
former smoker, as the 25% additional risk is assumed to be eliminated only 
when a person becomes a former smoker. This 75% maximum benefit that a 
smoker could obtain from reduced consumption is based on the maximum 
difference in the risk of lung cancer (82%), ischemic heart disease (57%) and 
COPD (80%) between high-intensity and low-intensity smokers compared to 
former smokers.14 
c. Long-term scenario: maximum effect over ten years. Like scenario b, but with 
a 75% reduction in consumption affecting prevalence (Ip=0.75); population of 
former smokers remains constant in relation to the baseline, with a decrease 
in prevalence and an increase in non-smokers population.  
As for the effectiveness analysis of the smoke-free measurement package, reduction in risk 
in non-smokers by reducing second-hand exposure to tobacco smoke was also considered. 
We estimated the new prevalence of expected active smoking as a result of implementing 
the interventions, for each sex and age group, as follows:  
 
𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐e𝑝𝑜𝑠𝑡 = 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐e𝑝𝑟𝑒 - (𝐸𝑚 ∗ 𝐼𝑝 ∗ 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐e𝑝𝑟𝑒) 
 
Where Prevalencepre is the prevalence of smokers before implementing the intervention, 
Em is the effectiveness of the intervention measured in terms of relative reduction in 
consumption; and Ip is the proportion of variation in consumption that impacts on smoking 
prevalence, assuming 0.50 for the short-term and mid-term scenarios, and 0.75 for the long-




















Model calibration and validation process 
To calibrate the model, we compared disease specific mortality rates for each sex and age 
group with local statistics; predicted rates within 10% of the references were considered 
acceptable. In case of greater deviation, we modified risk equations. External validation was 
accomplished by checking the model results against those results of other epidemiological 
and clinical studies not used for equation estimation and development.  
Cost data 
Direct medical costs during the year the event occurred were estimated for chronic 
conditions; costs of follow-up were also estimated. A literature search was conducted 
to identify reported costs of events. A common costing methodology was developed 
to estimate costs through a micro-costing or macro-costing approach, depending on 
the availability and quality of information. A Microsoft Excel spreadsheet was 
designed for each event, identifying frequency, use rate and unit cost of health 
resources employed for each event. Ad hoc micro-costing exercises were 
constructed based on communications with experts, clinical guidelines and a review 
of healthcare facility records. Costs of malign ncies other than lung cancer were 
based on lung cancer costs and on an expert consensus obtained through a Delphi 
method exercise. Where sufficient local information was unavailable, extrapolation 
was used to approximate costs of events; the average of the proportion represented 
by the cost of the event over the per capita GDP in Argentina, Chile and Mexico was 
used, and over this average proportion, per capita GDP of the country of interest was 
applied to obtain estimates. All costs were first estimated in the local currency in 
2015. Then, these costs were converted to US dollars using the 2015 exchange 
rates published by each country’s central bank.  
Inclusion of passive smoking and perinatal effects 
Given that the model does not directly calculate the consequences of passive smoking and 
perinatal effects, based on the results of previous studies, it was estimated that these 
causes impose an additional burden of 13.6% for men and 12% for women.31 Main 






















Estimates for impact of smoke-free air intervention 
Effectiveness of current smoke-free policies depends on their implementation level, 
assuming that the level reflects the degree of implementation compared to no intervention or 
to an inferior level of implementation. We adjusted effectiveness to the level of measures 
that were effectively implemented in each country, independently of its legislation. We 
estimated the new smoking prevalence that was expected as a result of implementing the 
intervention, for each sex and age group. To obtain data on the benefits of implementing 
smoke-free policies to populate the simulation model, we performed a three-stage 
systematic review; including a review of documents published on international organizations 
and internet sites related to tobacco control, an overview of systematic reviews on the 
effectiveness of smoke-free interventions in any country and, finally, a systematic review of 
this intervention in Latin American countries (see supplementary file for the detailed 
methodology of these approaches). 
For the first stage, we searched in seven key organizations/documents related to public 
health and tobacco control: MPOWER, Tobacco Atlas, FCTC, Pan-American Health 
Organization (PAHO), International Tobacco Control Policy Evaluation Project (ITC Project): 
Global Adult Tobacco Survey (GATS) and Tobacco Free Kids. Specifically, we searched for 
the definitions and effectiveness of smoke-free air interventions, reported effectiveness of 
the different levels of implementation, specific level of implementation reported for each 
country included, and methodology used in the classification of policy implementation. 
Secondly, we performed an overview of systematic reviews on the effectiveness of smoke-
free air interventions. Finally, we performed a systematic review on the effectiveness of 
smoke free interventions in the seven countries of interest.  
The following electronic databases were used: MEDLINE, EMBASE, CENTRAL, 
SOCINDEX, EconLit, LILACS, NBER, CRD and Cost Effectiveness Analysis Registry, the 
International Tobacco Health Conference Paper Index and Cochrane Tobacco Addiction 
Review Group register. Grey literature was reviewed from ministries of health, ministries of 
finance, PAHO and databases containing regional congress proceedings. Updated 
information on tobacco use prevalence was obtained from local tobacco GATS surveys, 
where available, or national risk factor surveys. Researchers from the participating countries 
provided additional information on civil registrations, vital statistics and hospital discharge 
databases to estimate specific case fatality rates. 
Findings from the Levy systematic review show that the complete implementation of smoke-




















implementation could reduce consumption by 2.8% (range 1.4 to 4.2), whereas a minimal 
implementation could diminish consumption by 1.4% (range 0.7 to 2.1). 
We have incorporated a sensitivity analysis on the uncertainty regarding the effectiveness of 
the intervention (the most important input of the model in this analysis) and all results include 
the base case estimate and the lower and upper values. 
 
RESULTS  
The overview yielded two relevant systematic reviews and data from two key 
resources.12,14,32,33 After identifying 77 studies from 21 countries, Frazier et al. found clear 
evidence of a positive impact of national smoking free-air bans on reducing mortality for 
associated smoking-related illnesses and improving cardiovascular health outcomes; indeed, 
a legislative smoking ban led to improved health outcomes through reduction in second-
hand smoking.32 Another review including 37 studies showed evidence that smoke-free 
policies reduced tobacco use among workers when implemented in worksites or by 
communities.14  
 
The systematic review of smoke free-air policies in Latin America yielded four studies 
reporting the effects of smoke-free policies in the region at different levels.34-37 In Uruguay, 
the simultaneous implementation of the measures set out in the WHO-FCTC was an 
effective strategy to reduce the prevalence of tobacco use in a short period of time.34 In 
Argentina, an immediate decrease in acute coronary syndrome admissions was observed 
after implementing smoke-free laws compared with no change.35 In Mexico City, support for 
smoke-free laws increased once these laws were implemented by a greater rate of change 
than in other cities.36 Shan et al. found that greater exposure to tobacco control polices was 
significantly associated with quitting.37  Figure 1 shows the flow chart of both reviews.  
We found that Argentina, Brazil, Chile, Colombia and Peru have a complete level of 
implementation of smoke-free policies, whereas Bolivia and Mexico have a moderate level of 
implementation of smoke-free policies.  
With the current level of implementation of smoke-free policies in the seven countries 
(Argentina, Bolivia, Brazil, Chile, Colombia, Mexico, and Peru) over the next 10 years, a total 
of 137,121 deaths and 944,868 events could be averted. Specifically, 399,581 cardiac 




















cancer could be averted; moreover, 3.84 million years of life could be added. Averted events 
could represent savings totalling USD 9.6 billion over the same period. With the largest 
population in the group of studied countries, Brazil could avert 80,489 deaths, 610,276 
events, with over 2.4 million years lived, and 5.7 billion in savings. Argentina and Chile come 
in second and third places in the number of averted deaths, with 19,261 and 12,897, 
respectively (see Table 2).  
Bolivia and Mexico have a 30% of implementation of the moderate level of smoke-free 
policies, corresponding to 3-5 and 6-7 of public places in MPOWER tool, respectively. If 
these two countries advanced to a full implementation of this moderate ban, in the next 10 
years, Bolivia would avert an additional 466 deaths, 1,660 events, would add 11,957 years 
lived, and save US$ 28.1 million whereas Mexico would avert an additional 3,104 deaths, 
17,756 events, add 84,794 years lived and save US$ 283.6 million in health costs (data not 
shown in tables).  Argentina, Brazil, Chile, Colombia and Peru are already in the complete 
level of ban policies, with 60% implementation, and could potentially advance to a total 
accomplishment of the full ban. In the case that smoke-free strategies were fully 
implemented across all countries, these could avert 178,615 premature deaths, 492,115 
cardiac events, 144,829 cerebrovascular events, 311,129 COPD, 77,399 cancer diagnosis 
over ten years. A total of 5.0 million years of life would be added and a total of US$ 13.1 
billion in direct healthcare expenses of diseases attributable to smoking would be saved 
(Table 3). Brazil would lead in number of averted deaths with 80,489 but followed by 
Argentina and Mexico with 28,657 and 25,683, respectively. The same occurs with savings; 
Brazil would save US$ 5.7 billion, followed by Mexico and Argentina with US$ 2.6 billion and 
US$ 2.4 billion, respectively.  
 
DISCUSSION 
Our findings show that smoking represents a significant health and economic burden in 
seven countries in Latin America, with 345,373 deaths, 2.2 million disease events, and US$ 
25.4 billion health expenses. Article 8 of WHO-FCTC requires adoption and implementation 
of measures to reduce exposure to tobacco smoke in indoor workplaces, public places, and 
public transport. However, disparities in the enforcement of this Article suggest that these 
benefits are not being fully realized.38 The benefits of smoke-free workplace policies extend 
to changing societal norms around SHS exposure in the home in LMICs. Smoke-free 





















As mentioned, if the smoke-free strategy were fully implemented, the seven countries could 
avert nearly 180,000 premature deaths, almost 500,000 cardiac events, almost 150,000 
cerebrovascular events, and almost 80,000 new cancer diagnosis over ten years. Studies 
throughout Latin America provide support for the results of our study, both in terms of the 
estimation of the overall burden and the potential outcomes of the implementation of smoke-
free strategies. Using the SimSmoke model, it has been projected that as a result of the 
highest level MPOWER measures adopted between 2007 and 2014, worldwide, almost 22 
million premature smoking-attributable deaths would be averted and the most deaths were 
averted due to adoption of increased cigarette taxes, closely followed by comprehensive 
smoke-free laws; however, nearly half of the world’s population remains uncovered by even 
a single MPOWER policy.17 
Evidence shows comprehensive smoke-free laws have an immediate and substantial 
effect of reducing hospital admissions due to acute myocardial infarction.40,41 In 
Chile, a significant abrupt reduction was observed in urban municipalities.40 The 
same effect was observed in Uruguay.41 It has also been shown that in high-, low- 
and middle-income countries, associations between being employed in a smoke-free 
workplace and living in a smoke-free home exist, suggesting that the accelerated 
implementation of comprehensive smoke-free public place policies is likely to result 
in population health gains in these settings.42 The lowest prevalence rates of SHS 
exposure in the workplace were found in Uruguay (16.5%), Mexico (18.6%) and 
Brazil (23.3); and men were more exposed to SHS at their workplaces than 
women.43 Of note, an abrupt ban could potentially lead to some distress and 
stigmatization of heavy smokers; consequently, measures should be accompanied 
with programs to help people quit or other interventions for coping with the 
situation.44 45 
A successful smoke-free implementation may require engagement by national and local 
health authorities, NGOs, external funders, and other stakeholders; in Colombia, for 
example, implementation was possible despite scarce government resources and 
enforcement agencies focused on public security.46 Indeed, compliance with legislation 
relate to the enforcement infrastructure, the local government efforts in training enforcement 
agents.47 On the other hand, tobacco companies implement tactics to fight tobacco control 
strategies such as influencing through front groups, allying with third parties, lobbying, media 
campaigns, legal challenges, commissioning research, hiring consultants, using financial 




















specifically oriented to tax-policy; confusing debates, stimulating smuggling to support their 
claims, and working to divert  funds.48 For this reason, governments should continue to 
pursue evidence-based measures to reduce smoking, excluding tobacco companies from 
any policy involvement; health organisations should continue to press for action while 
scientists should reject involvement with the tobacco industry.49   
Our study has some limitations. We estimated direct medical costs related to smoking, a part 
of total financial burden of tobacco, but not indirect costs. The model did not include certain 
conditions related to exposure to exposure such as breast cancer, diabetes, liver cancer or 
kidney failure. It was not always possible to include high-quality epidemiological information 
to populate the model, due to its scarcity. Also, changes in demographic, economic and 
healthcare system characteristics over time were not included in the model. However, our 
findings offer a robust estimate of financial burden of smoking in seven countries of Latin 
America, with the best available sources of information in each country, applying a uniform 
and replicable method, and including a sensitivity analysis for the effectiveness of the 
intervention.  
The challenges in implementing smoke-free policies that affect Latin America are not 
unique to the region; weak legislation, lack of compliance, the need for monitoring 
laws, and tobacco industry attempts to undermine progress.50 The number of 
countries in the  Americas with national regulations that establish 100% smoke-free 
environments in any public place and in closed work and on public transport was 16 
by 2016.51 Sharing expertise across the region, funding of civil society, and the 
commitment by governments to implement the FCTC will be critical to future 
progress. Given the immense progress made in the region since 2006, when the first 
Latin American country became smoke-free, and the global momentum for smoke-
free workplaces and public places, Latin America is well positioned to become one 
day a 100% smoke-free region.50  
In conclusion, our results suggest that smoke-free strategies can successfully 
contribute to the reduction of the overall burden of tobacco use and should be 
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Table 1. Main parameters considered for the simulation model 
Indicator  Argentina Bolivia Brazil Chile Colombia Mexico Peru Uruguay 
Population (2015) 43,416,755 10,724,705 207,847,528 17,948,141 48,228,704 127,017,224 31,376,670 3,431,555 
Smoking prevalence1         
  Male 23.4 20.1 18.0 35.2 20.1 19.8 23.5 27.7 
  Female 18.6 17.7 11.3 31.3 9.9 6.4 15.3 17.7 
Crude mortality rate (Male / Female per 10,000)
2
 
Acute myocardial infarction  46.1 / 33.1 8.4 / 5.5 16.0 / 11.0 8.3 / 4.9 19.0 / 13.7 19.9 / 13.9 74.6 / 57.3 8.2 / 5.0 
Other cardiovascular causes  118.7/104.5 0.9 / 0.5 3.8 / 2.9 7.4 / 8.4 2.3 / 1.7 2.2 / 3.1 51.8 / 57.2 26.5 / 27.9 
Cerebrovascular disease 52.5 / 43.9 8.4 / 8.0 8.8 / 7.9 9.8 / 9.6 8.5 / 9.3 8.1 / 8.1 52.6 / 50.7 8.8 / 11.4 
Pneumonia/influenza 104.4 / 72.4 17.4 / 15.9 9.1 / 8.5 4.2 / 4.0 3.6 / 3.1  4.0/ 3.1 221.0/199.0 5.9 / 6.2 
COPD 4.3 / 1.9 1.1 / 1.3 6.6 / 4.5 3.7 / 2.8 7.9 / 5.8 7.5 / 5.6 33.2 / 25.3 9.0 / 3.2 
Lung cancer  15.6 / 4.6 3.7 / 3.1 4.3 / 2.5 3.9 / 2.2 3.3 / 1.9 2.5 / 1.2 13.5 / 10.4 12.6 / 3.5 
Estimated direct health costs of smoking-related conditions in USD millions     
Acute myocardial infarction 3,242 5,114 5,006 3944 3,835 4,848.6 2,663 13,188 
Other cardiovascular causes  2,432 3,835 1,881 2702 1,534 3,190.4 1,850 12,584 
Annual cardiovascular follow-up.  1,283 2,024 409 1444 34,795 1,240.6 1,171 4,082 
Cerebrovascular disease
3




















Indicator  Argentina Bolivia Brazil Chile Colombia Mexico Peru Uruguay 
Pneumonia/influenza 217 276 361 235 325 1,309.9 174 1,220 
COPD
4
 4,394 3,969 4,824 6133 3,463 9,236.2 4,363 386 
Lung cancer
5
 17,392 8,862 12,279 21727 10,499 13,792.6 14,081 40,122 
Mouth cancer
5
 12,523 6,381 9,602 15644 7,560 9,930.6 9,251 28,888 
Oesophageal cancer  14,610 7,444 12,161 18251 8,820 11,585.7 11,828 33,703 
Stomach cancer
5
 14,262 7,267 15,074 17816 8,610 11,309.9 11,546 32,900 
Pancreatic cancer
5
 11,827 6,026 11,616 14774 7,140 9,378.9 9,575 2,728 
Kidney cancer
5
 12,523 6,381 4,632 15644 7,560 9,930.6 10,138 28,888 
Tax revenue on smoking
6
 1,926.2 21.5 9,511 1,346.5 174 2,237.4 73.5 211.4 
GDP (2015)
6
 583,168.6 33,197 1,774,725 240,215.7 292,080.1 1,144,331.3 192,083.7 53,442.7 
GDP per capita (2015)
6 13,432 3,095 8,539 13,384 6,056 9,009 6,122 15,574 
Price elasticity of demand  -0.299 -0.85 -0.48 -0.45 -0.780 -0.45 -0.7 -0.55 
Total health expenditure (% GDP) 4.8 6.3 8.3 7.8 7.2 6.3 5.5 8.8 
Abbreviations: COPD, chronic obstructive pulmonary disease; GDP, gross domestic product.  
Key: 1. Population ≥35 years expressed in millions; 2. Mortality rate per 10.000 people; 3. Values include first and following years, as a summary, only 
first year is included in table. 4. COPD mild, moderate and serious included. 5. Treatment costs of following years are included. 6. In millions of US 



























(Lower and Upper values) 
Averted deaths 
Averted events 
Years lived due to 
prevented premature 
death and disability  





COPD Cancer Total events 
Argentina 19,261 30,505 11,051 27,657 8,899 97,373 463,005 1,582  
 (9,761; 28,500) (15,459; 45,137) (5,600; 16,353) (14,016; 40,925) (4,510; 13,168) (49,345; 144,082) (234,636; 685,107) (801.8; 2,341.0) 
Bolivia 807 470 888 1,286 233 3,684 20,724 48.6  
 (405; 1,206) (236; 702) (446; 1,921) (645; 1,921) (117; 349) (1,849; 5,505)  (10,403; 30,964) (24.4; 72.6) 
Brazil 80,489 299,264 59,189 133,364 37,969 610,276 2,403,991 5,739  
 (40,995; 118,483) (152,421; 440,530) (30,146; 87,129) (67,925; 196,317) (19,339; 55,893) (310,826; 898,351) (1,224,400; 3,538,773) (2,923.1; 8,448.4) 
Chile 12,897 16,226 15,095 29,330 5,204 78,752 337,615 1,291  
 (6,569; 18,984) (8,264; 23,885) (7,688; 22,220) (14,938; 43,175) (2,650; 7,660) (40,110; 115,925) (171,954; 496,984) (657.5; 1,900.4) 
Colombia 11,035 34,823 15,424 18,015 4,262 83,559 287,500 424.6  




















Mexico 5,381 13,897 3,382 11,364 2,023 36,046 146,965 491.6 
 (2,701; 8,039) (6,976; 20,763) (1,698; 5,054) (5,704; 16,979) (1,015; 3,022) (18,094; 53,857) (73,771; 219,583) (246.8; 734.5) 
Peru 7,251 4,396 6,813 14,099 2,618 35,178 177,923 375,7 
 (3,684; 10,702) (2,233; 6488) (3,461; 10,055) (7,163; 20,809) (1,330; 3,864) (17,872; 51,918) (90,392; 262,595) (190,9; 554,5) 
Total 137,121 399,581 111,842 235,115 61,208 944,868 3,837,723  9,576.80 




























Table 3. Ten-year Cumulative benefits to be obtained by implementing complete smoke-free air strategy 
Country 
Point Estimate 




Years of life due to 
premature death and 
disability  
Savings in  





COPD Cancer Total events 
Argentina 28,657 45,386 16,443 41,150 13,240 144,876 688,882 2,353.9 
 (13,786; 46,433) (21,834; 73,539) (7,910; 26,642) (19,796; 66,676) (6,369; 21,453) (69,694; 234,743) (331,394; 1,116,743) (1,132.4; 3,814.1) 
Bolivia 3,852 2,244 4,239 6,137 1,113 17,586 98,917 232.0 
 (1,901; 5,863) (1,107; 3,414) (2,092; 6,451) (3,028; 9,339) (549; 1,694) (8,677; 26,762) (48,803; 150,529) (114.5; 353.1) 
Brazil 80,489 299,264 59,189 133,364 37,969 610,276 2,403,991 5,739.2 
 (40,995; 118,483) (152,421; 440,530) (30,146; 87,129) (67,925; 196,317) (19,339; 55,893) (310,826; 898,351) (1,224,400; 3,538,773) (2,923.1; 8,448.4) 
Chile 12,897 16,226 15,095 29,330 5,204 78,752 337,615 1,291 




















Colombia 18,151 57,279 25,370 29,632 7,011 137,444 472,903 698.5 
 (8,706; 29,270) (27,473; 92,368) (12,169; 40,912) (14,213; 47,784) (3,363; 11,306) (65,924; 221,640) (226,823; 762,594) (335.0; 1,126.4) 
Mexico 25,683 66,329 16,145 54,239 9,654 172,050 701,476 2,346.4 
 (12,671; 39,083) (32,725; 100,938) (7,965; 24,569) (26,760; 82,540) (4,763; 14,691) (84,885; 261,820) (346,090; 1,067,486) (1,157.7; 3,570.7) 
Peru 8,886 5,387 8,348 17,277 3,208 43,106 218,026 460.4 
 (4,347; 14,310) (2,635; 8,676) (4,084; 13,445) (8,451; 27,823) (1,569; 5,167) (21,086; 69,420) (106,651; 351,117) (225.2; 741.4) 
Total 178,615 492,115 144,829 311,129 77,399 1,204,090 4,921,810 13,121 
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